A Phase II/III, Multicenter, Randomized, Double-Blind, Double-Dummy Study to Assess Similarity of the Efficacy, Pharmacokinetics, Safety and Immunogenicity of Abatacept Administered Subcutaneously or Intravenously in Japanese Subjects With Rheumatoid Arthritis, Receiving Background Methotrexate, and Experiencing an Inadequate Response to Methotrexate
Latest Information Update: 17 Sep 2021
Price :
$35 *
At a glance
- Drugs Abatacept (Primary) ; Abatacept (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 01 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Jun 2012 Results presented at the 13th Annual Congress of the European League Against Rheumatism.
- 06 Jun 2012 Planned number of patients changed from 120 to 118 as reported by ClinicalTrials.gov.